BioAge Labs will expand clinical development of its oral brain-penetrant small molecule NLRP3 inhibitor, BGE-102, into ophthalmology, initiating a Phase 1b/2a proof-of-concept trial in patients …
Read More
Insilico Medicine and Hygtia Therapeutics have entered a global co-development and licensing agreement for ISM8969, an orally available, blood-brain barrier–penetrant NLRP3 inhibitor intended for central …
Read More
London-based Isomorphic Labs broke the news with yet another pharmaceutical partnership, announcing a new research collaboration with Johnson & Johnson’s Janssen Biotech unit aimed at …
Read More
Isomorphic Labs has announced a cross-modality research collaboration with Johnson & Johnson, aimed at integrating its AI-based drug design engine with Johnson & Johnson’s experimental …
Read More
Merge Labs has emerged from stealth with $252 million in funding to develop non-implantable brain–computer interfaces that use ultrasound and molecular approaches rather than electrodes. …
Read More
Insilico Medicine reported the deployment of its Nach01 multimodal foundation model on Microsoft Discovery, Microsoft’s Azure-based platform for AI-driven research and development. The demonstration illustrates …
Read More
